Literature DB >> 31220951

Proteomic signatures of neuroinflammation in Alzheimer's disease, multiple sclerosis and ischemic stroke.

Camilla Thygesen1,2, Martin Rössel Larsen2, Bente Finsen1.   

Abstract

Introduction: Inflammation is integral in the neuropathology of both chronic and acute neurological disorders. Knowing the inflammatory profile is important for clarification of disease mechanisms, diagnostic purposes, and ultimately treatment options. Areas covered: A systematic review was performed on literature from PubMed using the search terms 'Alzheimer's disease' (AD) or "multiple sclerosis" (MS) or "ischemic stroke" and 'proteomics'. Inflammatory proteins were assessed in blood, cerebrospinal fluid (CSF), and post-mortem brain tissue. Regulated inflammatory proteins across compartments and disorders mainly consisted of innate immune proteins, acute phase proteins and oxidative stress response proteins. In addition, immunoglobulin chains were signature proteins of MS, reflecting additional involvement of adaptive immunity. The Chitinase 3-like protein 1 was increased in ten original articles on MS and in three on AD supporting its implication in these diseases. Furthermore, CNS/CSF AD inflammatory proteins were matched to a CNS myeloid cell proteome implicating Alpha-2-Macroglobulin and Annexin A1 in AD pathogenesis. Expert opinion: Proteomics is an excellent technique for profiling inflammatory proteins in tissues and cells, but still targeted approaches are required for profiling of very low abundance proteins and peptides. Knowing the inflammatory signature of brain tissue, CSF, blood, and CNS myeloid cells holds the potential to point to novel mechanistic aspects of neurological diseases.

Entities:  

Keywords:  Alzheimer’s disease; CNS myeloid cells; complement system; immunoglobulin; innate immunity; ischemic stroke; mass spectrometry-based proteomics; microglia; multiple sclerosis; neuroinflammation

Mesh:

Substances:

Year:  2019        PMID: 31220951     DOI: 10.1080/14789450.2019.1633919

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN: 1478-9450            Impact factor:   3.940


  5 in total

Review 1.  Knowledge gaps in Alzheimer's disease immune biomarker research.

Authors:  David G Morgan; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2021-05-13       Impact factor: 21.566

2.  Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.

Authors:  Gustaf Boström; Eva Freyhult; Johan Virhammar; Daniel Alcolea; Hayrettin Tumani; Markus Otto; Rose-Marie Brundin; Lena Kilander; Malin Löwenmark; Vilmantas Giedraitis; Alberto Lleó; Christine A F von Arnim; Kim Kultima; Martin Ingelsson
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

3.  Why Inclusion Matters for Alzheimer's Disease Biomarker Discovery in Plasma.

Authors:  Mostafa J Khan; Heather Desaire; Oscar L Lopez; M Ilyas Kamboh; Renã A S Robinson
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.160

4.  CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes.

Authors:  Maria L Elkjaer; Arkadiusz Nawrocki; Tim Kacprowski; Pernille Lassen; Anja Hviid Simonsen; Romain Marignier; Tobias Sejbaek; Helle H Nielsen; Lene Wermuth; Alyaa Yakut Rashid; Peter Høgh; Finn Sellebjerg; Richard Reynolds; Jan Baumbach; Martin R Larsen; Zsolt Illes
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

5.  Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis.

Authors:  Ellen F Mosleth; Christian Alexander Vedeler; Kristian Hovde Liland; Anette McLeod; Gerd Haga Bringeland; Liesbeth Kroondijk; Frode Steingrimsen Berven; Artem Lysenko; Christopher J Rawlings; Karim El-Hajj Eid; Jill Anette Opsahl; Bjørn Tore Gjertsen; Kjell-Morten Myhr; Sonia Gavasso
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.